Alkermes PLC

Most Recent

  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Amgen Rises by 2% as XBI’s Large-Cap Stocks Rally

    Amgen closed at $157.60 and was trading above its 50- and 100-day moving averages. The stock also witnessed a rise in trading volumes.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Alexion Continues to Rise on FDA’s Approval of Kanuma

    Alexion Pharmaceuticals (ALXN) gained 2.5% on December 10, 2015. The stock went up after the FDA (Food and Drug Administration) approved its drug, Kanuma.

    By Peter Neil
  • uploads///blood _
    Earnings Report

    Alkermes in the Third Quarter: A Performance Overview

    Alkermes (ALKS) reported its third-quarter results on October 23. It generated net revenues of $248.7 million, a 14% YoY growth.

    By Daniel Collins
  • uploads///NKTR
    Company & Industry Overviews

    What Does Nektar Therapeutics’ Valuation Trend Indicate?

    Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).

    By Kenneth Smith
  • uploads///ALKS
    Company & Industry Overviews

    Exploring Alkermes’ Financial Performance in Fiscal 2017

    Alkermes (ALKS) generated total revenues of $903.0 million in fiscal 2017 compared with $745.6 million in fiscal 2016.

    By Kenneth Smith
  • uploads///ALKS RD pipeline
    Company & Industry Overviews

    An Insight into Alkermes’ R&D Pipeline

    Alkermes’ ALKS3831 is an investigational oral medicine is targeted for the treatment of schizophrenia.

    By Kenneth Smith
  • uploads///ALKS
    Company & Industry Overviews

    A Look at Alkermes’ Diabetes Product Portfolio

    According to Alkermes, ~26.0 million people in the US and 382.0 million people globally are affected by diabetes.

    By Kenneth Smith
  • uploads///ALKS Aristada sales
    Company & Industry Overviews

    A Deeper Look at Alkermes’ Key Marketed Products

    Alkermes’ (ALKS) Aristada is an intramuscular injectable suspension for the treatment of schizophrenia.

    By Kenneth Smith
  • uploads///nerve cell _
    Company & Industry Overviews

    Analysts’ Ratings for Alkermes and Its Peers in February 2018

    Of the 12 analysts covering Alkermes (ALKS) in February, five analysts gave ALKS a “buy” rating. Seven analysts gave it a “hold” rating.

    By Kenneth Smith
  • uploads///virus _
    Company & Industry Overviews

    Analyst Ratings for Vanda Pharmaceuticals and Peers in February

    Of the six analysts covering Vanda Pharmaceuticals in February 2018, two of them have given the stock a “strong buy” rating.

    By Kenneth Smith
  • uploads///Portfolio Breakdown of the FNGAX
    Fund Managers

    What’s the Sector Composition of the FNGAX?

    The Franklin International Growth Fund invests “in the equity securities of mid- and large-capitalization companies outside the U.S. with long-term growth potential.”

    By David Ashworth
  • uploads///Portfolio Breakdown of the FNGAX
    Fund Managers

    The Franklin International Growth Fund’s Portfolio Moves in YTD 2016

    In the past 12 months until May 2016, Franklin International Growth Fund (FNGAX) has witnessed increased exposure to discretionary and healthcare stocks.

    By David Ashworth
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI News as of March 16: Mid-Caps Under Pressure

    Given selling pressures, XBI’s 18 mid-cap stocks went down marginally on average, losing 0.4% on March 16. Eight stocks advanced while ten stocks declined.

    By Peter Neil
  • uploads///FNGAXs Top Invested Geographies
    Fund Managers

    What You Should Know about the Franklin International Growth Fund

    The Franklin International Growth Fund – Class A (FNGAX) was incepted in June 2008 and has an expense ratio of 1.4%.

    By David Ashworth
  • uploads///Fidelity Growth Company Fund Vs Peers
    Company & Industry Overviews

    How Has the Fidelity Growth Company Fund Performed in 2016?

    The Fidelity Growth Company Fund (FDGRX) was among the top five largest funds in this peer group, managing assets worth $36.0 billion as of January 2016.

    By David Ashworth
  • uploads///Graph
    Miscellaneous

    Alkermes’s Aristada and Its FDA Approval for Schizophrenia

    Aristada was approved by the FDA and is projected to account for 10% to 30% of the LAI atypical antipsychotic market for schizophrenia patients in the US.

    By Margaret Patrick
  • uploads///Graph Part
    Company & Industry Overviews

    Top Ten of XBI Outperform by Market Cap

    The average return of the top ten IBB stocks was -4.73%, while the average return of top ten XBI stocks was -3.89% for the week ended September 4, 2015.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    What Led Large-Cap Stocks to Outperform Mid and Small Caps?

    Within the iShares Nasdaq Biotechnology ETF (IBB), for the week ending July 31, 2015, the top ten large-cap stocks had a weight of 56.59% of IBB’s portfolio.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.